Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs OMN 54 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CAMPAS
- Sponsors Omnitura Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.
- 24 Jul 2018 Planned initiation date changed from 1 Jan 2019 to 1 Sep 2018.